Biologic agents in psoriasis

Australasian Journal of Dermatology

Volumn 47, Issue 4, 2006, Pages 217-230

  Lee, Michael R ^a   Cooper, Alan J ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Alefacept; Efalizumab; Etanercept; Fusion protein; Infliximab; Monoclonal antibody; Psoriasis area and severity index; Recombinant cytokine

Indexed keywords

ADALIMUMAB; ALEFACEPT; CALCIPOTRIOL; CYCLOSPORIN; DENILEUKIN DIFTITOX; EFALIZUMAB; ETANERCEPT; ETRETIN; HYDROXYUREA; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11;

ANEMIA; APLASTIC ANEMIA; ASTHENIA; CHILL; DEMYELINATING DISEASE; DRUG MECHANISM; DYSPNEA; ERYTHEMA MULTIFORME; FEVER; FLUSHING; HEADACHE; HUMAN; HYPOTENSION; IMMUNOMODULATION; INFECTION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; LICHENOID ERUPTION; MULTIPLE SCLEROSIS; MYALGIA; MYELITIS; NAUSEA; NONHODGKIN LYMPHOMA; OPTIC NEURITIS; PATHOGENESIS; PHARYNGITIS; PRURITUS; PSORIASIS; REVIEW; RHINITIS; SEIZURE; SEPSIS; SIDE EFFECT; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; TUBERCULOSIS; URTICARIA; VOMITING;

ANTIBODIES, MONOCLONAL; BIOLOGICAL RESPONSE MODIFIERS; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PSORIASIS; RECOMBINANT FUSION PROTEINS;

EID: 33749551488     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2006.00286.x     Document Type: Review

References (77)

1. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. 2002; 46: 1-23.
2. Chisholm PL, Williams CA, Jones WE, Majeau GR, Oleson FB, Burrus-Fischer B, Meier W, Hochman PS. The effects of an immunomodulatory LFA3-IgG1 fusion protein on nonhuman primates. Ther. Immunol. 1994; 1: 205-16.
3. Meier W, Gill A, Rogge M, Dabora R, Majeau GR, Oleson FB, Jones WE, Frazier D, Miatkowski K, Hochman PS. Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Ther. Immunol. 1995; 2: 159-71.
4. Miller GT, Hochman PS, Meier W, Tivard R, Bixler SA, Rosa MD, Wallner BP. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T-cell responses. J. Exp. Med. 1993; 178: 211-22.
5. Majeau GR, Whitty A, Yim K, Meier W, Hochman PS. Low affinity binding of an LFA-3/IgG1 fusion protein to CD2+ T cells is independent of cell activation. Cell Commun. Adhes. 1999; 7: 267-79.
6. Sanders ME, Makgoba MW, Sharrow SO, Stephany D, Springer TA, Young HA, Shaw S. Human memory T lymphocytes express increased levels of three adhesion molecules (LFA-3, CD2 and LFA-1) and three other molecules (UHCL 1, CDw29, and Pgp-1) and have enhanced IFN-γ production. J. Immunol. 1988; 140: 1401-7.
7. Lebwohl M, Christophers E, Langley R, Ortonne J, Roberts J, Griffiths CEM. An international, randomized, double-blind, placebo controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch. Dermatol. 2003; 139: 719-27.
8. Krueger GG, Callis KP. Development and use of alefacept to treat psoriasis. J. Am. Acad. Dermatol. 2003; 49: S87-97.
9. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. 2001; 345: 248-55.
10. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J. Am. Acad. Dermatol. 2002; 47: 821-33.
11. Gottlieb AB, Casale TB, Frankel E, Goffe B, Lowe N, Ochs HD, Roberts JL, Washenik K, Vaishnaw AK, Gordon KB. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J. Am. Acad. Dermatol. 2003; 49: 816-25.
12. Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T et al. Humanisation of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J. Immunol. 1996; 157: 4986-95.
13. Krueger J, Gottlieb A, Miller B, Dedrick R, Garovoy M, Walicke P. Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking (Abstract). J. Invest. Dermatol. 2000; 115: 333.
14. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A. Efalizumab for patients with moderate to severe plaque psoriasis. A randomised controlled trial. JAMA 2003; 290: 3073-80.
15. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. 2003; 349: 2004-13.
16. Gottlieb AB, Gordon KB, Lebwohl MG, Caro IV, Walicke PA, Li N, Leonardi C. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J. Drugs Dermatol. 2004; 3: 614-24.
17. Gottlieb A, Krueger JG, Bright R, Ling M, Lebwohl M, Kang S et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J. Am. Acad. Dermatol. 2000; 42: 428-35.
18. Gottlieb AB, Krueger JG, Wittkowski K, Dedrich R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease. Immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch. Dermatol. 2002; 138: 591-600.
19. Papp K, Bissonnette R, Krueger JG, Carey W, Gratton D, Gulliver WP et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J. Am. Acad. Dermatol. 2001; 45: 665-74.
20. Leonardi C. Efalizumab in the treatment of psoriasis. Derm. Ther. 2004; 17: 393-400.
21. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, Meyer zum Büschenfelde KH, Fleischer B. T cells involved in psoriasis vulgaris belong to the Th-1 subset. J. Invest. Dermatol. 1994; 102: 145-9.
22. Bonfiati C, Ameglio F. Cytokines in psoriasis. Int. J. Dermatol. 1999; 38: 241-51.
23. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T-cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2 and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 1999; 113: 752-9.
24. Barker JN, Jones ML, Mitra RS, Crockett-Torabe E, Fantone JC, Kunkel SL, Warren JS, Dixit VM, Nickoloff BJ. Modulation of keratinocyte-derived interleukin-8 which is chemotactic for neutrophils and lymphocytes. Am. J. Pathol 1991; 139: 869-76.
25. Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, May LT, Kupper TS, Sehgal PB, Gottlieb AB. Interleukin-6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc. Natl Acad. Sci. 1989; 86: 6367-71.
26. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J. Clin. Invest. 1996; 98: 1878-87.
27. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, Volk HD, Döcke WD. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J. Clin. Invest. 1998; 101: 783-94.
28. Friedrich M, Docke WD, Klein A, PhilipS, Volk HD, Sterry W, Asadullah K. Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in psoriasis. J. Invest. Dermatol. 2002; 118: 672-7.
29. Asadullah K, Döcke WD, Ebeling M, Friedrich M, Belbe G, Audring H, Volk HD, Sterry W. Interleukin 10 treatment of psoriasis. Clinical results of a phase 2 trial. Arch. Dermatol. 1999; 135: 187-92.
30. Reich K, Brück M, Gräfe A, Vente C, Neumann C, Garbe C. Treatment of psoriasis with interleukin-10 (Letter). J. Invest. Dermatol. 1998; 6: 1235-6.
31. McInnes IB, Illei GG, Danning CL, Yarboro CH, Crane M, Kuroiwa T et al. IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J. Immunol. 2001; 167: 4075-82.
32. Kimball AB, Kawamura T, Tejura K, Boss C, Hancox AR, Vogel JC, Steinberg SM, Turner MI, Blauvelt A. Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10. Arch. Dermatol. 2002; 138: 1341-6.
33. Trepicchio WL, Ozawa M, Walters IB, Kikuchi T, Gilleaudeau P, Bliss JL, Schwertschlag U, Dorner AJ, Kruger JG. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J. Clin. Invest. 1999; 104: 1527-37.
34. Nickoloff BJ, Karabin GD, Barker JNWN, Griffiths CEM, Sarma V, Mitra RS, Elder JT, Kunkel SL, Dixit VM. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am. J. Pathol. 1991; 138: 129-40.
35. Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J. Rheumatol. 1999; 26: 7-15.
36. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000; 356: 385-90.
37. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W. Etanercept treatment of psoriatic arthritis: safety, efficacy and effect on disease progression. Arthritis Rheum. 2004; 50: 2264-72.
38. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS et al. A randomised trial of etanercept as monotherapy for psoriasis. Arch. Dermatol. 2003; 139: 1627-32.
39. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 2003; 349: 2014-22.
40. Krueger GG, Lebwohl M, Wang A, Zitnik R. Continuance of etanercept after early incomplete response in patients with psoriasis (Abstract). J. Am. Acad. Dermatol. 2004; 50: 141.
41. Gottlieb A, Gordon K, Wang A, Zitnik R. Withdrawal from etanercept after successful clinical response in psoriasis patients: disease characteristics and the durability of treatment response (Abstract). J. Am. Acad. Dermatol. 2004; 50: 146.
42. Leonardi CL, Elewski B, Camisa C, Zitnik R. The efficacy and safety of etanercept in the re-treatment of psoriasis after relapse (Abstract). J. Am. Acad. Dermatol. 2004; 50: 146.
43. Krueger GG, Woolley JM, Zitnik R. The effects of etanercept therapy on patient reported outcomes for patients with moderate to severe psoriasis (Abstract). J. Am. Acad. Dermatol. 2004; 50: 155.
44. Etanercept (package insert). Seattle, WA: Immunex Corporation and Wyeth-Ayerst Pharmaceuticals; 2002.
45. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002; 46: 3151-8.
46. Gelfand JM, Berlin J, VanVoorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch. Dermatol. 2003; 139: 1425-9.
47. Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L. Rheumatoid arthritis and malignant lymphomas. Curr. Opin. Rheumatol. 2004; 16: 254-61.
48. Goffe B, Cather JC. Etanercept: an overview. J. Am. Acad. Dermatol. 2003; 49: S105-11.
49. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359: 579-80.
50. Bleumink GS, ter Borg EJ, Ramselaar CG, Stricker BH. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology 2001; 40: 1317-19.
51. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br. J. Dermatol. 2002; 146: 118-21.
52. Strober BE. Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab (Letter). Arch. Dermatol. 2004; 140: 366.
53. Scallon BJ, Morre MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7: 251-9.
54. Martinez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm. Bowel Dis. 2001; 7: 323-6.
55. Steinfeld S, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjogren's syndrome. A pilot study. Arthritis Rheum. 2001; 44: 2371-5.
56. Chan JJ, Gebauer K. Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous tumour necrosis factor-alpha antibody (infliximab). Australas. J. Dermatol. 2003; 44: 116-20.
57. Newland MR, Weinstein A, Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int. J. Dermatol. 2002; 41: 449-52.
58. O'Quinn R, Miller JL. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis. Arch. Dermatol. 2002; 138: 644-8.
59. Oh C, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J. Am. Acad. Dermatol. 2000; 42: 829-30.
60. Wollina U, Konrad H. Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-alpha antibody. J. Eur. Acad. Dermatol. Venerol. 2002; 16: 127-9.
61. Ogilvie ALJ, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, Lüftl M. Treatment of psoriatic arthritis with antitumor necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br. J. Dermatol. 2001; 144: 587-9.
62. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J. Am. Acad. Dermatol. 2002; 46: 886-91.
63. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001; 357: 1842-7.
64. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J. Am. Acad. Dermatol. 2003; 48: 829-35.
65. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW, Menter A. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 2004; 51: 534-42.
66. Feldman SR, Bala M, Menter A, Gordon KB. The quality of life of patients with severe psoriasis treated with infliximab (Abstract). J. Am. Acad. Dermatol. 2004; 50: S2.
67. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998; 41: 1552-63.
68. Vergara G, Silvestre JF, Betlloch I, Vela P, Albares MP, Pascual JC. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch. Dermatol. 2002; 138: 1258-9.
69. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralising agent. N. Engl. J. Med. 2001; 345: 1098-104.
70. Lim WS, Powell RJ, Johnston ID. Tuberculosis and treatment with infliximab. N. Engl. J. Med. 2002; 346: 623-6.
71. Gottlieb AB. Infliximab for psoriasis. J. Am. Acad. Dermatol. 2003; 49: S112-17.
72. Lee MR, Cooper AJ. The use of infliximab in the treatment of psoriasis (Letter). Australas. J. Dermatol. 2004; 45: 193-5.
73. Kirby B, Marsland AM, Carmichael AJ, Griffiths CEM. Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin. Exp. Dermatol. 2001; 26: 27-9.
74. Chew AL, Bennett A, Smith CH, Barker J, Kirkham B. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br. J. Dermatol. 2004; 151: 492-6.
75. Adalimumab (package insert). North Chicago, IL: Abbot Laboratories; 2004.
76. Martin A, Gutierrez E, Muglia J, McDonald CJ, Guzzo C, Gottlieb A et al. A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB389IL-2) in patients with severe psoriasis. J. Am. Acad. Dermatol. 2001; 45: 871-81.
77. Skov L, Kragballe K, Zachariae C, Obitz ER, Holm EA, Jemec GBE et al. HuMax-CD4. A fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch. Dermatol. 2003; 139: 1433-9.